SlideShare uma empresa Scribd logo
1 de 36
Baixar para ler offline
ANGIOTENSIN CONVERTING ENZYME
INHIBITORS (ACE-Is) IN THE
MANAGEMENT OF MYOCARDIAL
INFARCTION
Emmanuel D Benjamín
OUTLINE
• Intro; MI- Management
• ACEIs- class definition
• Examples
• MOA
• Rationale for the use of ACEIs in MI
• RAAS
• SAR of ACEIs
• Pharmacology of a prototypical ACEI; CAPTOPRIL
• Pharmacology of Lisinopril
• Drug interractions
• Counselling points
• Side effects
• Discussion
• Conclusion
2
INTRO
• Myocardial infarction is myocardial necrosis caused by acute
occlusion of a coronary artery due to plaque rupture or erosion with
superimposed thrombosis.
• Approximately 1 million Americans will have a new or recurrent
myocardial infarction this year (National registry of myocardial
infarction). Nigeria?
• Coronary heart disease is the single largest cause of death in the
United States.
• The estimated direct and indirect costs of coronary heart disease to
GDP= $95.6 billion/year (National Registry of Myocardial infarction)
• Management involves non-drug measures and drug therapy,
including, thrombolytics, β- blockers, statins, ARBs, Antiplatelet
therapy, aldosterone receptor antagonism, ACE inhibitors.
3
DEFINITION OF CLASS
• ACEIs are drugs that competitively inhibit angiotensin converting
enzyme (ACE).
• Thus inhibiting the production of angiotensin II.
• ↓ TPR, hence BP
• ↓ aldosterone
• ↓ Na retetion
• ↓ H2O retention
4
EXAMPLES
• Captopril
• Enalapril
• Lisinopril
• Fosinopril
• Quinapril
• Trandolapril
• Benazepril
CLASSIFICATION OF ACEIs
(Based on Zn+2 binding moeity)
• Sulfhydryl-containing agents: Captopril (Active drug),
the first ACE inhibitor, Zofenopril,
Alacepril and Moveltipril.
• Dicarboxylate-containing agents: This is the largest
group, including: Enalapril, Ramipril,
Quinapril, Perindopril, Lisinopril (Active drug),
Benazepril, Cilazapril, Delapril and
Spirapril
• Phosphonate-containing agents: Fosinopril and SQ
29852
• Naturally occuring ACEIs; Casokinins and lactokinins,
breakdown products of casein and whey, occur
naturally after ingestion of milk products, especially
cultured milk. Their role in blood pressure control is
uncertain (Fitzgerald et al, 2004). 5
MOA
• Binding to ACE
• Inhibition of angiotensin II synthesis leading to decreased blood
pressure + cardiovascular protection from hemodynamically
mediated effects of angiotensis II on cardiac cells.
• cardiopretective action from angiotensinII effects on the heart.
6
RATIONALE FOR THE USE OF
ACEIs IN MI – THE RAAS
7
RAAS
• The renin-angiotensin-aldosterone system (RAAS) is a signaling pathway
responsible for regulating the body's blood pressure.
• Stimulated by low blood pressure or certain nerve impulses (e.g. in stressful
situations), the kidneys release an enzyme called renin. This triggers a
signal transduction pathway: renin splits the protein angiotensinogen,
producing angiotensin I. This is converted by another enzyme, the
angiotensin-converting enzyme (ACE), into angiotensin II.
• Angiotensin II not only causes blood vessels to narrow (vasoconstriction), it
also simultaneously stimulates the secretion of the water-retaining hormone
vasopressin (also called AVP) in the pituitary gland (hypophysis) as well as
the release of adrenaline, noradrenaline and aldosterone in the adrenal
gland.
8
RATIONALE FOR THE USE OF
ACEIs IN MI
• This underlines the role of the Renin-Angiotensin-Aldosterone
System (RAAS) in the pathological changes that occur post MI.
• RAAS contributes to the eccentric cardiac hypertrophy and fibrosis
seen in MI by stimulating the migration (Bell and Madri, 1990;
Dubey et al., 1995), proliferation (Daemen et al., 1991),
hypertrophy and increased ECF production by cardiac fibroblasts
(Villarreal et al., 1993; Crawford et al., 1994; Ostrom et al., 2003).
• RAAS also contributes to the hypertophy (Itoh et al., 1993), and
increased production of ECF by vascular smooth muscle cells
(Scott-Burden et al., 1990).
9
Rationale contd
• Angiotensin II acts directly on cells to induce the expression of
specific proto-oncogenes
• Angiotensin II rapidly (within minutes) increases steady-state levels
of mRNAs which alters the expression of several genes that
stimulate cell growth (hypertrophy and hyperplasia), including basic
fibroblast growth factor, platelet-derived growth factor, and
transforming growth factor ᵝ
• changes in cardiac preload (volume expansion owing to Na+
retention) and afterload (increased arterial blood pressure) probably
contribute to cardiac hypertrophy and remodeling(goodman and
gilman, 2006).
10
Rationale contd
• Arterial hypertension also contributes to hypertrophy and
remodeling of blood vessels.
11
SAR OF ACEIs (Rajeev et al, 2010)
12
SAR Contd
• The N-ring must contain a carboxylic acid to mimic the C-terminal
carboxylate of ACE substrates.
• Large hydrophobic heterocyclic rings (i.e., the N-ring) increase
potency and alter pharmacokinetic parameters.
• The zinc binding groups can be either sulfhydryl (A), a carboxylic
acid (B), or a phosphinic acid (C).
• The sulfhydryl group shows superior binding to zinc (the side chain
mimicking Phe in carboxylate and phosphinic acid compounds
compensates for the lack of a sulfhydryl group)
13
SAR Contd
• Sulfhydryl-containing compounds produce high incidence of skin
rash and taste disturbances.
• Sulfhydryl-containing compounds can form dimers and disulfides
which may shorten duration of action.
• Compounds which bind to zinc through either a carboxylate or
phosphinate mimic the peptide hydrolysis transition state.
• Esterification of the carboxylate or phosphinate produces an orally
bioavailable prodrug.
14
SAR Contd
• X is usually methyl to mimic the side chain of alanine. Within the
dicarboxylate series, when X equals n-butylamine (lysine side chain)
this produces a compound which does not require prodrug for oral
activity.
• Optimum activity occurs when stereochemistry of inhibitor is
consistent with L-amino acid stereochemistry present in normal
substrates
15
Structure of angiotensin I
16
Date of download:
10/23/2014
Copyright © The American College of Cardiology.
All rights reserved.
From: Are all angiotensin-converting enzyme inhibitors interchangeable?
J Am Coll Cardiol. 2001;37(5):1456-1460. doi:10.1016/S0735-1097(01)01161-5
The chemical structures of the 10 ACE inhibitors currently available in the U.S. The term “proven” refers to ACE inhibitors shown to
improve survival or reduce morbidity. ACEI = angiotensin-converting enzyme inhibitor.
Figure Legend:
CAPTOPRIL (CAPOTEN)
• Captopril was the first inhibitor for clinical trial.
• Reported to have a more favorable effect on QOL (Testa et al, 1993)
• According to the mechanism proposed by Ondetti and colleagues,
captopril interacts with the enzyme through several bonds, i.e.
electrostatic, hydrogenic and lipophilic connections.
• Among these, a co-ordinance bond formed between the free thiol
group of captopril and zinc ion in the active site of ACE.
18
Captopril contd
• INTERRACTION OF CAPTOPRIL WITH
ACE BINDING SITES(Vane, 1999 )
19
Captopril contd
• Captopril, the first ACE inhibitor to be marketed, is a potent ACE
inhibitor.
• It is the only ACE inhibitor approved for use in the United States
that contains a sulfhydryl moiety.
• Given orally, captopril is absorbed rapidly and has a bioavailability of
about 75%.
• Peak concentrations in plasma occur within an hour, and the drug is
cleared rapidly with a half-life of approximately 2 hours
20
Captopril contd
• Most of the drug is eliminated in urine, 40% to 50% as captopril and
the rest as captopril disulfide dimers and captopril-cysteine disulfide.
• The oral dose of captopril ranges from 6.25 to 150 mg two to three
times daily, with 6.25 mg three times daily or 25 mg twice daily being
appropriate for the initiation of therapy.
• Most patients should not receive daily doses in excess of 150 mg.
Since food reduces the oral bioavailability of captopril by 25% to
30%, the drug should be given 1 hour before meals
21
Lisinopril (PRINIVIL,
ZESTRIL).
• Lisinopril, the third ACE inhibitor approved for use in the United
States, is the lysine analogue of enalaprilat; unlike enalapril,
lisinopril itself is active (Goodman ad Gilman, 2004).
• In vitro, lisinopril is a slightly more potent ACE inhibitor than is
enalaprilat. Lisinopril is absorbed slowly, variably, and incompletely
(about 30%) after oral administration (not reduced by food); peak
concentrations in plasma are achieved in about 7 hours.
• It is cleared as the intact compound by the kidney, and its half-life in
plasma is about 12 hours.
Lisinopril contd
• Lisinopril does not accumulate in tissues.
• The oral dosage of lisinopril ranges from 5 to 40 mg daily (single or
divided dosage), with 5 and 10 mg daily being appropriate for the
initiation of therapy.
• A daily dose of 2.5 mg is recommended for patients with heart failure
who are hyponatremic or have renal impairment
23
ACEI DRUG INTERRACTIONS
24
Interractions contd
25
Counselling points for ACEIs
• Might feel dizzy when you start taking this medicine. Get up
gradually from sitting or lying position to minimize this effect. Sit or
lie down if patient becomes light headed or dizzy.
• Do not take potassium supplements or consume too much banana
while taking this medication unless your doctor instructs otherwise.
• When starting ACEIs, stop potassium-sparing diuretics, for 24 hours.
• Always start with low doses.
• Check renal function and electrolytes before starting ACEIs and
review after 1-2 weeks.
• Report promptly when untoward effects occur.
26
Common side effects of ACEIs
• Angioedema
• Fetotoxicity
• Skin rashes (esp. Captopril due to sulfhydryl group)
• Acute renal failure
• Dry cough
• Headache
• Nausea
• Dizziness
• Fatigue
27
DISCUSSION
• ACEIs increase survival when administered early after an acute
myocardial infarction (MI) (Khalil et al).
• The early benefit of ACE inhibitor therapy
suggests that starting ACE inhibitors within 24 h has an
effect on the infarcted myocardium either by limiting infarct
size or by reducing infarct expansion (GISSI Trial, 1994)
28
Effect of ACE-inhibitor therapy on cumulative mortality during days 0 to 30 in all trials
combined.
ACE Inhibitor Myocardial Infarction Collaborative Group
Circulation. 1998;97:2202-2212
Copyright © American Heart Association, Inc. All rights reserved.
DISCUSSION contd
• Since activation of the renin-angiotensin
system has been shown to be an independent predictor of
ischemic event (Alderman et al, 1991), ACEIs help prevent MI.
• Additionally, ACE inhibition has been shown to counteract
several atherosclerotic processes including thrombosis, lowdensity
lipoprotein oxidation, proliferation of vascular
smooth muscle cells and local accumulation of neutrophils
contributing to MI (Mancini, 1996).
• Preliminary data have shown that ACE
inhibition improves endogenous fibrinolytic function (Moriyama et al
1997).
30
CONCLUSION
• ACEIs have proven to be aces in the hole for virtually all cardiac
patients as the RAAS appears to be a constant meddler in majority
of cardiovascular events, which contribute a high percentage to
morbidity and mortality worlwide.
• They have a proven efficacy in the management of MI especially
when started early in the post-infarction period.
• A meta-analysis of all published, major trials investigating the use of
an ACEI after an MI conclusively supports a role for ACEI therapy in
the early phase and ongoing management of MI (Latini et al, 1995).
31
REFERENCES
• FitzGerald RJ, Murray BA, Walsh DJ; Murray, BA; Walsh, DJ (2004).
"Hypotensive peptides from milk proteins". The Journal of nutrition
134 (4): 980S–8S. PMID 15051858
• Goodman & Gilman's The Pharmacological Basis Of Therapeutics -
11th Ed. (2006)
• Bell, L., and Madri, J.A. Influence of the angiotensin system on
endothelial and smooth muscle cell migration. Am. J.
Pathol., 1990, 137:7-12. PUBMED
• Daemen, M.J.M.P., Lombardi, D.M., Bosman, F.T., and Schwartz,
S.M. Angiotensin II induces smooth muscle cell proliferation in the
normal and injured rat arterial wall. Circ. Res., 1991, 68:450-456.
PUBMED
•
32
REFERENCES
• Villarreal, F.J., Kim, N.N., Ungab, G.D., Printz, M.P., and Dillmann,
W.H. Identification of functional angiotensin II receptors on rat
cardiac fibroblasts. Circulation, 1993, 88:2849-286l. PUBMED
• Crawford, D.C., Chobanian, A.V., and Brecher, P. Angiotensin II
induces fibronectin expression associated with cardiac fibrosis in the
rat. Circ. Res., 1994, 74:727-739. PUBMED
• Ostrom, R.S., Naugle, J.E., Hase, M., et al. Angiotensin II enhances
adenylyl cyclase signaling via Ca++/calmodulin: Gq-Gs cross-talk
regulates collagen production in cardiac fibroblasts. J. Biol. Chem.,
2003, 278:24461-24468. PUBMED
• Testa, M.A., Anderson, R.B., Nackley, J.F., Hollenberg, N.K., and the
Quality-of-Life Hypertension Study Group. Quality of life and
antihypertensive therapy in men: A comparison of captopril with
enalapril. New Engl. J. Med., 1993, 328:907-913. PUBMED
33
REFERENCES
• Itoh, H., Mukoyama, M., Pratt, R.E., Gibbons, G.H., and Dzau, V.J.
Multiple autocrine growth factors modulate vascular smooth muscle
cell growth response to angiotensin II. J. Clin.
Invest., 1993, 91:2268-2274. PUBMED
• Scott-Burden, T., Hahn, A.W.A., Resink, T.J., and Buhler, F.R.
Modulation of extracellular matrix by angiotensin II: Stimulated
glycoconjugate synthesis and growth in vascular smooth muscle
cells. J. Cardiovasc. Pharmacol., 1990, 16(suppl. 4):S36-S41
• Rajeev Kumar, Ramji Sharma, Khamji Barwa, Ram kumar Roy, Aran
Kumar, Atul Baruwa. Moder developmet in ACE Ihibitors. Der
Pharmacia Lettre, 2010; 2(3):388-419
• Mohammed E. Khalil, Abul W. Basher, Edward J. Brown, JR,
Imad A. Alhaddad. A Remarkable Medical Story: Benefits of
Angiotensin-Converting Enzyme Inhibitors in Cardiac Patients.
Journal of the American College of Cardiology. 2001. 37(7): 34
REFERENCES
• Gruppo Italiano per lo Studio della Sopravvivenza nell’Infarto
Miocardico. GISSI-3: effects of lisinopril and transdermal glyceryl
trinitrate singly and together on six-week mortality and ventricular
function after acute MI. Lancet 1994;343:1115–22
• Ng, K.K.F. & Vane, J.R. Conversion of angiotensin I to angiotensin II.
Nature 216,
762–766 (1967)
35
CREDITS:
• Pharm. Khadijat S Adejumo
• Pharm. Nicholas A
• Pharm. Ibrahim James Oyibo
• Mr Isa Buba and Mr Nasiru
THANK YOU ALL FOR LISTENING.
QUESTIONS?
36

Mais conteúdo relacionado

Mais procurados

Comparative Study of Omeprazole and Esomeprazole
Comparative Study of Omeprazole and EsomeprazoleComparative Study of Omeprazole and Esomeprazole
Comparative Study of Omeprazole and EsomeprazolePharmacy Universe
 
Adrenergic agonists
Adrenergic agonistsAdrenergic agonists
Adrenergic agonistsLeul Mesfin
 
UNIT II SYMPATHOLYTIC AGENTS
UNIT II SYMPATHOLYTIC AGENTSUNIT II SYMPATHOLYTIC AGENTS
UNIT II SYMPATHOLYTIC AGENTSSONALI PAWAR
 
H1 & H2 receptor antagonist
H1 & H2 receptor antagonistH1 & H2 receptor antagonist
H1 & H2 receptor antagonistAshok Jangra
 
Drugs Acting on Cholinergic System 1
Drugs Acting on Cholinergic System 1Drugs Acting on Cholinergic System 1
Drugs Acting on Cholinergic System 1Pravin Prasad
 
Beta adrenoceptor agonists
Beta adrenoceptor agonistsBeta adrenoceptor agonists
Beta adrenoceptor agonistsTural Abdullayev
 
H1 and h2 receptor antagonist
H1 and h2 receptor antagonistH1 and h2 receptor antagonist
H1 and h2 receptor antagonistShubham Sharma
 
The Pharmacology of Beta-Blockers
The Pharmacology of Beta-BlockersThe Pharmacology of Beta-Blockers
The Pharmacology of Beta-BlockersPrijay Bakrania
 
Gaba receptors & drugs acting on them
Gaba receptors & drugs acting on themGaba receptors & drugs acting on them
Gaba receptors & drugs acting on themchandiniyrao
 
UNIT II: DRUGS ACTING ON AUTONOMIC NERVOUS SYSTEM
UNIT II: DRUGS ACTING ON AUTONOMIC NERVOUS SYSTEMUNIT II: DRUGS ACTING ON AUTONOMIC NERVOUS SYSTEM
UNIT II: DRUGS ACTING ON AUTONOMIC NERVOUS SYSTEMSONALI PAWAR
 
Adrenergic blockers
Adrenergic blockersAdrenergic blockers
Adrenergic blockersSahil Patil
 
Receptor Pharmacology
Receptor PharmacologyReceptor Pharmacology
Receptor PharmacologyTulasi Raman
 
Phase ii biotransform of drugs
Phase ii biotransform of drugsPhase ii biotransform of drugs
Phase ii biotransform of drugsRajat Mahamana
 

Mais procurados (20)

Mm
MmMm
Mm
 
Comparative Study of Omeprazole and Esomeprazole
Comparative Study of Omeprazole and EsomeprazoleComparative Study of Omeprazole and Esomeprazole
Comparative Study of Omeprazole and Esomeprazole
 
Adrenergic agonists
Adrenergic agonistsAdrenergic agonists
Adrenergic agonists
 
UNIT II SYMPATHOLYTIC AGENTS
UNIT II SYMPATHOLYTIC AGENTSUNIT II SYMPATHOLYTIC AGENTS
UNIT II SYMPATHOLYTIC AGENTS
 
ACE Inhibitors
ACE InhibitorsACE Inhibitors
ACE Inhibitors
 
H1 & H2 receptor antagonist
H1 & H2 receptor antagonistH1 & H2 receptor antagonist
H1 & H2 receptor antagonist
 
Drugs Acting on Cholinergic System 1
Drugs Acting on Cholinergic System 1Drugs Acting on Cholinergic System 1
Drugs Acting on Cholinergic System 1
 
Beta adrenoceptor agonists
Beta adrenoceptor agonistsBeta adrenoceptor agonists
Beta adrenoceptor agonists
 
H1 and h2 receptor antagonist
H1 and h2 receptor antagonistH1 and h2 receptor antagonist
H1 and h2 receptor antagonist
 
The Pharmacology of Beta-Blockers
The Pharmacology of Beta-BlockersThe Pharmacology of Beta-Blockers
The Pharmacology of Beta-Blockers
 
Nitrates
NitratesNitrates
Nitrates
 
Antihistamines
AntihistaminesAntihistamines
Antihistamines
 
Drugs affecting renin-angiotensin system
Drugs affecting renin-angiotensin systemDrugs affecting renin-angiotensin system
Drugs affecting renin-angiotensin system
 
Gaba receptors & drugs acting on them
Gaba receptors & drugs acting on themGaba receptors & drugs acting on them
Gaba receptors & drugs acting on them
 
UNIT II: DRUGS ACTING ON AUTONOMIC NERVOUS SYSTEM
UNIT II: DRUGS ACTING ON AUTONOMIC NERVOUS SYSTEMUNIT II: DRUGS ACTING ON AUTONOMIC NERVOUS SYSTEM
UNIT II: DRUGS ACTING ON AUTONOMIC NERVOUS SYSTEM
 
Adrenergic blockers
Adrenergic blockersAdrenergic blockers
Adrenergic blockers
 
ACE inhibitors
ACE inhibitorsACE inhibitors
ACE inhibitors
 
Receptor Pharmacology
Receptor PharmacologyReceptor Pharmacology
Receptor Pharmacology
 
Phase ii biotransform of drugs
Phase ii biotransform of drugsPhase ii biotransform of drugs
Phase ii biotransform of drugs
 
Para sympathomimetics
Para sympathomimeticsPara sympathomimetics
Para sympathomimetics
 

Semelhante a ANGIOTENSIN CONVERTING ENZYME NHIBITORS IN THE MANAGEMENT OF MYOCARDIAL INFARCTION

Effects of anesthesia and surgery on renal function
Effects of anesthesia and surgery on renal functionEffects of anesthesia and surgery on renal function
Effects of anesthesia and surgery on renal functionHASSAN RASHID
 
Advances in Medical Management of Heart Failure
Advances in Medical Management of Heart FailureAdvances in Medical Management of Heart Failure
Advances in Medical Management of Heart FailurePraveen Nagula
 
Renin-Angiotensin Aldeaterone System RAAS
Renin-Angiotensin Aldeaterone System RAASRenin-Angiotensin Aldeaterone System RAAS
Renin-Angiotensin Aldeaterone System RAASDrMohamoudLectures
 
ACE INHIBITORS.pptx
ACE INHIBITORS.pptxACE INHIBITORS.pptx
ACE INHIBITORS.pptxChhavi Singh
 
Antihypertensive drugs
Antihypertensive drugsAntihypertensive drugs
Antihypertensive drugsKarun Kumar
 
Cardiac anesthesia board lecture
Cardiac anesthesia board lectureCardiac anesthesia board lecture
Cardiac anesthesia board lectureOthman Abdulmajeed
 
Drugs acting on Renin Angiotensin Aldosterone system
Drugs acting on Renin Angiotensin Aldosterone system Drugs acting on Renin Angiotensin Aldosterone system
Drugs acting on Renin Angiotensin Aldosterone system Dr Htet
 
Potential new therapies in heart failure
Potential new therapies in heart failurePotential new therapies in heart failure
Potential new therapies in heart failureAnirudhya J
 
160465212 case-study-new-03
160465212 case-study-new-03160465212 case-study-new-03
160465212 case-study-new-03homeworkping7
 
Blood pressure changes during
Blood pressure changes duringBlood pressure changes during
Blood pressure changes duringmagdy elmasry
 
Agents affecting renin angiotensin aldosterone system (RAAS)
Agents affecting renin angiotensin aldosterone system (RAAS) Agents affecting renin angiotensin aldosterone system (RAAS)
Agents affecting renin angiotensin aldosterone system (RAAS) Ravish Yadav
 

Semelhante a ANGIOTENSIN CONVERTING ENZYME NHIBITORS IN THE MANAGEMENT OF MYOCARDIAL INFARCTION (20)

Antihipertensivos
AntihipertensivosAntihipertensivos
Antihipertensivos
 
CHF.pptx
CHF.pptxCHF.pptx
CHF.pptx
 
Effects of anesthesia and surgery on renal function
Effects of anesthesia and surgery on renal functionEffects of anesthesia and surgery on renal function
Effects of anesthesia and surgery on renal function
 
Advances in Medical Management of Heart Failure
Advances in Medical Management of Heart FailureAdvances in Medical Management of Heart Failure
Advances in Medical Management of Heart Failure
 
Acei
AceiAcei
Acei
 
Renin-Angiotensin Aldeaterone System RAAS
Renin-Angiotensin Aldeaterone System RAASRenin-Angiotensin Aldeaterone System RAAS
Renin-Angiotensin Aldeaterone System RAAS
 
ACE INHIBITORS.pptx
ACE INHIBITORS.pptxACE INHIBITORS.pptx
ACE INHIBITORS.pptx
 
Ace
AceAce
Ace
 
Antihypertensive drugs
Antihypertensive drugsAntihypertensive drugs
Antihypertensive drugs
 
Antihypertensive lecture
Antihypertensive lecture Antihypertensive lecture
Antihypertensive lecture
 
A2
A2A2
A2
 
Cardiac anesthesia board lecture
Cardiac anesthesia board lectureCardiac anesthesia board lecture
Cardiac anesthesia board lecture
 
Drugs acting on Renin Angiotensin Aldosterone system
Drugs acting on Renin Angiotensin Aldosterone system Drugs acting on Renin Angiotensin Aldosterone system
Drugs acting on Renin Angiotensin Aldosterone system
 
Potential new therapies in heart failure
Potential new therapies in heart failurePotential new therapies in heart failure
Potential new therapies in heart failure
 
AcE Inhibitors in Hypertension
AcE Inhibitors in HypertensionAcE Inhibitors in Hypertension
AcE Inhibitors in Hypertension
 
160465212 case-study-new-03
160465212 case-study-new-03160465212 case-study-new-03
160465212 case-study-new-03
 
Blood pressure changes during
Blood pressure changes duringBlood pressure changes during
Blood pressure changes during
 
EMPHASIS HF
EMPHASIS HFEMPHASIS HF
EMPHASIS HF
 
Agents affecting renin angiotensin aldosterone system (RAAS)
Agents affecting renin angiotensin aldosterone system (RAAS) Agents affecting renin angiotensin aldosterone system (RAAS)
Agents affecting renin angiotensin aldosterone system (RAAS)
 
RAAS mbbs
RAAS mbbsRAAS mbbs
RAAS mbbs
 

Último

TARGET DELINEATION IN CERVIX CANCER BY DR KANHU
TARGET DELINEATION IN CERVIX CANCER BY DR KANHUTARGET DELINEATION IN CERVIX CANCER BY DR KANHU
TARGET DELINEATION IN CERVIX CANCER BY DR KANHUKanhu Charan
 
SMA Implementation science seminar (Day 1).pptx
SMA Implementation science seminar (Day 1).pptxSMA Implementation science seminar (Day 1).pptx
SMA Implementation science seminar (Day 1).pptxAbdirahmanWaseem
 
Problems associated with the production of recombinant protein.pdf
Problems associated with the production of recombinant protein.pdfProblems associated with the production of recombinant protein.pdf
Problems associated with the production of recombinant protein.pdfNetHelix
 
Brief introduction to information ecosystem x public health.pptx
Brief introduction to information ecosystem x public health.pptxBrief introduction to information ecosystem x public health.pptx
Brief introduction to information ecosystem x public health.pptxTina Purnat
 
Human Skeletal System_By Anupam Das......
Human Skeletal System_By Anupam Das......Human Skeletal System_By Anupam Das......
Human Skeletal System_By Anupam Das......anupamdas2143
 
SGK PHÙ PHỔI CẤP ĐHYHN .pdf
SGK PHÙ PHỔI CẤP ĐHYHN                   .pdfSGK PHÙ PHỔI CẤP ĐHYHN                   .pdf
SGK PHÙ PHỔI CẤP ĐHYHN .pdfHongBiThi1
 
CELL BLOCK PREPARATION AND ITS IMPORTANCE
CELL BLOCK PREPARATION AND ITS IMPORTANCECELL BLOCK PREPARATION AND ITS IMPORTANCE
CELL BLOCK PREPARATION AND ITS IMPORTANCEShubhadip Ghosh
 
Ortho Products Franchise-solace biotech limited
Ortho Products Franchise-solace biotech limitedOrtho Products Franchise-solace biotech limited
Ortho Products Franchise-solace biotech limitedSBL DIGITAL
 
TARGET DELINEATION IN VULVAL CANCER BY DR KANHU
TARGET DELINEATION IN VULVAL CANCER BY DR KANHUTARGET DELINEATION IN VULVAL CANCER BY DR KANHU
TARGET DELINEATION IN VULVAL CANCER BY DR KANHUKanhu Charan
 
Spinal cord Gross anatomy with Clinical Anatomy.pptx
Spinal cord Gross anatomy with Clinical Anatomy.pptxSpinal cord Gross anatomy with Clinical Anatomy.pptx
Spinal cord Gross anatomy with Clinical Anatomy.pptxsiddharthroy26587
 
Cholesterol Biosynthesis and catabolism for MBBS, Lab. MEd. BDS.pptx
Cholesterol Biosynthesis  and catabolism for MBBS, Lab. MEd. BDS.pptxCholesterol Biosynthesis  and catabolism for MBBS, Lab. MEd. BDS.pptx
Cholesterol Biosynthesis and catabolism for MBBS, Lab. MEd. BDS.pptxRajendra Dev Bhatt
 
INTRODUCTION TO THE FORENSIC SCIENCE.ppt
INTRODUCTION TO THE FORENSIC SCIENCE.pptINTRODUCTION TO THE FORENSIC SCIENCE.ppt
INTRODUCTION TO THE FORENSIC SCIENCE.pptKavitha Krishnan
 
HERPES SIMPLEX VIRUS 12032019 TUESDAY pptx
HERPES SIMPLEX VIRUS 12032019 TUESDAY  pptxHERPES SIMPLEX VIRUS 12032019 TUESDAY  pptx
HERPES SIMPLEX VIRUS 12032019 TUESDAY pptxPulkitMittal54
 
Tracheostomy .pdf ENT by QuickMedTALK. getting things done on time
Tracheostomy .pdf ENT by QuickMedTALK. getting things done on timeTracheostomy .pdf ENT by QuickMedTALK. getting things done on time
Tracheostomy .pdf ENT by QuickMedTALK. getting things done on timeQuick MedTalk
 
Routine Medicine Laboratory Testing _ CÁC XÉT NGHIỆM THƯỜNG QUY ÁP DỤNG TRON...
Routine Medicine Laboratory Testing  _ CÁC XÉT NGHIỆM THƯỜNG QUY ÁP DỤNG TRON...Routine Medicine Laboratory Testing  _ CÁC XÉT NGHIỆM THƯỜNG QUY ÁP DỤNG TRON...
Routine Medicine Laboratory Testing _ CÁC XÉT NGHIỆM THƯỜNG QUY ÁP DỤNG TRON...DUY NGUYEN PHUC
 
Ten lessons learnt as anesthetist.pptx
Ten  lessons  learnt as anesthetist.pptxTen  lessons  learnt as anesthetist.pptx
Ten lessons learnt as anesthetist.pptxtusharchokshi1
 
Neurological Evaluation of Acute Ischemic stroke in Emergency Room
Neurological Evaluation of Acute Ischemic stroke in Emergency RoomNeurological Evaluation of Acute Ischemic stroke in Emergency Room
Neurological Evaluation of Acute Ischemic stroke in Emergency RoomSudhir Kumar
 
(IDE)and(IVD),QMS,21 CFR part820 , 801)
(IDE)and(IVD),QMS,21 CFR part820  , 801)(IDE)and(IVD),QMS,21 CFR part820  , 801)
(IDE)and(IVD),QMS,21 CFR part820 , 801)chahattyagi200
 
EMBRYOLOGY AND FOETAL DEVELOPMENT-mayu.pdf
EMBRYOLOGY AND FOETAL DEVELOPMENT-mayu.pdfEMBRYOLOGY AND FOETAL DEVELOPMENT-mayu.pdf
EMBRYOLOGY AND FOETAL DEVELOPMENT-mayu.pdfMayuriGamit2
 

Último (20)

TARGET DELINEATION IN CERVIX CANCER BY DR KANHU
TARGET DELINEATION IN CERVIX CANCER BY DR KANHUTARGET DELINEATION IN CERVIX CANCER BY DR KANHU
TARGET DELINEATION IN CERVIX CANCER BY DR KANHU
 
SMA Implementation science seminar (Day 1).pptx
SMA Implementation science seminar (Day 1).pptxSMA Implementation science seminar (Day 1).pptx
SMA Implementation science seminar (Day 1).pptx
 
Problems associated with the production of recombinant protein.pdf
Problems associated with the production of recombinant protein.pdfProblems associated with the production of recombinant protein.pdf
Problems associated with the production of recombinant protein.pdf
 
Brief introduction to information ecosystem x public health.pptx
Brief introduction to information ecosystem x public health.pptxBrief introduction to information ecosystem x public health.pptx
Brief introduction to information ecosystem x public health.pptx
 
Human Skeletal System_By Anupam Das......
Human Skeletal System_By Anupam Das......Human Skeletal System_By Anupam Das......
Human Skeletal System_By Anupam Das......
 
Oral disorders .pptx
Oral disorders .pptxOral disorders .pptx
Oral disorders .pptx
 
SGK PHÙ PHỔI CẤP ĐHYHN .pdf
SGK PHÙ PHỔI CẤP ĐHYHN                   .pdfSGK PHÙ PHỔI CẤP ĐHYHN                   .pdf
SGK PHÙ PHỔI CẤP ĐHYHN .pdf
 
CELL BLOCK PREPARATION AND ITS IMPORTANCE
CELL BLOCK PREPARATION AND ITS IMPORTANCECELL BLOCK PREPARATION AND ITS IMPORTANCE
CELL BLOCK PREPARATION AND ITS IMPORTANCE
 
Ortho Products Franchise-solace biotech limited
Ortho Products Franchise-solace biotech limitedOrtho Products Franchise-solace biotech limited
Ortho Products Franchise-solace biotech limited
 
TARGET DELINEATION IN VULVAL CANCER BY DR KANHU
TARGET DELINEATION IN VULVAL CANCER BY DR KANHUTARGET DELINEATION IN VULVAL CANCER BY DR KANHU
TARGET DELINEATION IN VULVAL CANCER BY DR KANHU
 
Spinal cord Gross anatomy with Clinical Anatomy.pptx
Spinal cord Gross anatomy with Clinical Anatomy.pptxSpinal cord Gross anatomy with Clinical Anatomy.pptx
Spinal cord Gross anatomy with Clinical Anatomy.pptx
 
Cholesterol Biosynthesis and catabolism for MBBS, Lab. MEd. BDS.pptx
Cholesterol Biosynthesis  and catabolism for MBBS, Lab. MEd. BDS.pptxCholesterol Biosynthesis  and catabolism for MBBS, Lab. MEd. BDS.pptx
Cholesterol Biosynthesis and catabolism for MBBS, Lab. MEd. BDS.pptx
 
INTRODUCTION TO THE FORENSIC SCIENCE.ppt
INTRODUCTION TO THE FORENSIC SCIENCE.pptINTRODUCTION TO THE FORENSIC SCIENCE.ppt
INTRODUCTION TO THE FORENSIC SCIENCE.ppt
 
HERPES SIMPLEX VIRUS 12032019 TUESDAY pptx
HERPES SIMPLEX VIRUS 12032019 TUESDAY  pptxHERPES SIMPLEX VIRUS 12032019 TUESDAY  pptx
HERPES SIMPLEX VIRUS 12032019 TUESDAY pptx
 
Tracheostomy .pdf ENT by QuickMedTALK. getting things done on time
Tracheostomy .pdf ENT by QuickMedTALK. getting things done on timeTracheostomy .pdf ENT by QuickMedTALK. getting things done on time
Tracheostomy .pdf ENT by QuickMedTALK. getting things done on time
 
Routine Medicine Laboratory Testing _ CÁC XÉT NGHIỆM THƯỜNG QUY ÁP DỤNG TRON...
Routine Medicine Laboratory Testing  _ CÁC XÉT NGHIỆM THƯỜNG QUY ÁP DỤNG TRON...Routine Medicine Laboratory Testing  _ CÁC XÉT NGHIỆM THƯỜNG QUY ÁP DỤNG TRON...
Routine Medicine Laboratory Testing _ CÁC XÉT NGHIỆM THƯỜNG QUY ÁP DỤNG TRON...
 
Ten lessons learnt as anesthetist.pptx
Ten  lessons  learnt as anesthetist.pptxTen  lessons  learnt as anesthetist.pptx
Ten lessons learnt as anesthetist.pptx
 
Neurological Evaluation of Acute Ischemic stroke in Emergency Room
Neurological Evaluation of Acute Ischemic stroke in Emergency RoomNeurological Evaluation of Acute Ischemic stroke in Emergency Room
Neurological Evaluation of Acute Ischemic stroke in Emergency Room
 
(IDE)and(IVD),QMS,21 CFR part820 , 801)
(IDE)and(IVD),QMS,21 CFR part820  , 801)(IDE)and(IVD),QMS,21 CFR part820  , 801)
(IDE)and(IVD),QMS,21 CFR part820 , 801)
 
EMBRYOLOGY AND FOETAL DEVELOPMENT-mayu.pdf
EMBRYOLOGY AND FOETAL DEVELOPMENT-mayu.pdfEMBRYOLOGY AND FOETAL DEVELOPMENT-mayu.pdf
EMBRYOLOGY AND FOETAL DEVELOPMENT-mayu.pdf
 

ANGIOTENSIN CONVERTING ENZYME NHIBITORS IN THE MANAGEMENT OF MYOCARDIAL INFARCTION

  • 1. ANGIOTENSIN CONVERTING ENZYME INHIBITORS (ACE-Is) IN THE MANAGEMENT OF MYOCARDIAL INFARCTION Emmanuel D Benjamín
  • 2. OUTLINE • Intro; MI- Management • ACEIs- class definition • Examples • MOA • Rationale for the use of ACEIs in MI • RAAS • SAR of ACEIs • Pharmacology of a prototypical ACEI; CAPTOPRIL • Pharmacology of Lisinopril • Drug interractions • Counselling points • Side effects • Discussion • Conclusion 2
  • 3. INTRO • Myocardial infarction is myocardial necrosis caused by acute occlusion of a coronary artery due to plaque rupture or erosion with superimposed thrombosis. • Approximately 1 million Americans will have a new or recurrent myocardial infarction this year (National registry of myocardial infarction). Nigeria? • Coronary heart disease is the single largest cause of death in the United States. • The estimated direct and indirect costs of coronary heart disease to GDP= $95.6 billion/year (National Registry of Myocardial infarction) • Management involves non-drug measures and drug therapy, including, thrombolytics, β- blockers, statins, ARBs, Antiplatelet therapy, aldosterone receptor antagonism, ACE inhibitors. 3
  • 4. DEFINITION OF CLASS • ACEIs are drugs that competitively inhibit angiotensin converting enzyme (ACE). • Thus inhibiting the production of angiotensin II. • ↓ TPR, hence BP • ↓ aldosterone • ↓ Na retetion • ↓ H2O retention 4
  • 5. EXAMPLES • Captopril • Enalapril • Lisinopril • Fosinopril • Quinapril • Trandolapril • Benazepril CLASSIFICATION OF ACEIs (Based on Zn+2 binding moeity) • Sulfhydryl-containing agents: Captopril (Active drug), the first ACE inhibitor, Zofenopril, Alacepril and Moveltipril. • Dicarboxylate-containing agents: This is the largest group, including: Enalapril, Ramipril, Quinapril, Perindopril, Lisinopril (Active drug), Benazepril, Cilazapril, Delapril and Spirapril • Phosphonate-containing agents: Fosinopril and SQ 29852 • Naturally occuring ACEIs; Casokinins and lactokinins, breakdown products of casein and whey, occur naturally after ingestion of milk products, especially cultured milk. Their role in blood pressure control is uncertain (Fitzgerald et al, 2004). 5
  • 6. MOA • Binding to ACE • Inhibition of angiotensin II synthesis leading to decreased blood pressure + cardiovascular protection from hemodynamically mediated effects of angiotensis II on cardiac cells. • cardiopretective action from angiotensinII effects on the heart. 6
  • 7. RATIONALE FOR THE USE OF ACEIs IN MI – THE RAAS 7
  • 8. RAAS • The renin-angiotensin-aldosterone system (RAAS) is a signaling pathway responsible for regulating the body's blood pressure. • Stimulated by low blood pressure or certain nerve impulses (e.g. in stressful situations), the kidneys release an enzyme called renin. This triggers a signal transduction pathway: renin splits the protein angiotensinogen, producing angiotensin I. This is converted by another enzyme, the angiotensin-converting enzyme (ACE), into angiotensin II. • Angiotensin II not only causes blood vessels to narrow (vasoconstriction), it also simultaneously stimulates the secretion of the water-retaining hormone vasopressin (also called AVP) in the pituitary gland (hypophysis) as well as the release of adrenaline, noradrenaline and aldosterone in the adrenal gland. 8
  • 9. RATIONALE FOR THE USE OF ACEIs IN MI • This underlines the role of the Renin-Angiotensin-Aldosterone System (RAAS) in the pathological changes that occur post MI. • RAAS contributes to the eccentric cardiac hypertrophy and fibrosis seen in MI by stimulating the migration (Bell and Madri, 1990; Dubey et al., 1995), proliferation (Daemen et al., 1991), hypertrophy and increased ECF production by cardiac fibroblasts (Villarreal et al., 1993; Crawford et al., 1994; Ostrom et al., 2003). • RAAS also contributes to the hypertophy (Itoh et al., 1993), and increased production of ECF by vascular smooth muscle cells (Scott-Burden et al., 1990). 9
  • 10. Rationale contd • Angiotensin II acts directly on cells to induce the expression of specific proto-oncogenes • Angiotensin II rapidly (within minutes) increases steady-state levels of mRNAs which alters the expression of several genes that stimulate cell growth (hypertrophy and hyperplasia), including basic fibroblast growth factor, platelet-derived growth factor, and transforming growth factor ᵝ • changes in cardiac preload (volume expansion owing to Na+ retention) and afterload (increased arterial blood pressure) probably contribute to cardiac hypertrophy and remodeling(goodman and gilman, 2006). 10
  • 11. Rationale contd • Arterial hypertension also contributes to hypertrophy and remodeling of blood vessels. 11
  • 12. SAR OF ACEIs (Rajeev et al, 2010) 12
  • 13. SAR Contd • The N-ring must contain a carboxylic acid to mimic the C-terminal carboxylate of ACE substrates. • Large hydrophobic heterocyclic rings (i.e., the N-ring) increase potency and alter pharmacokinetic parameters. • The zinc binding groups can be either sulfhydryl (A), a carboxylic acid (B), or a phosphinic acid (C). • The sulfhydryl group shows superior binding to zinc (the side chain mimicking Phe in carboxylate and phosphinic acid compounds compensates for the lack of a sulfhydryl group) 13
  • 14. SAR Contd • Sulfhydryl-containing compounds produce high incidence of skin rash and taste disturbances. • Sulfhydryl-containing compounds can form dimers and disulfides which may shorten duration of action. • Compounds which bind to zinc through either a carboxylate or phosphinate mimic the peptide hydrolysis transition state. • Esterification of the carboxylate or phosphinate produces an orally bioavailable prodrug. 14
  • 15. SAR Contd • X is usually methyl to mimic the side chain of alanine. Within the dicarboxylate series, when X equals n-butylamine (lysine side chain) this produces a compound which does not require prodrug for oral activity. • Optimum activity occurs when stereochemistry of inhibitor is consistent with L-amino acid stereochemistry present in normal substrates 15
  • 17. Date of download: 10/23/2014 Copyright © The American College of Cardiology. All rights reserved. From: Are all angiotensin-converting enzyme inhibitors interchangeable? J Am Coll Cardiol. 2001;37(5):1456-1460. doi:10.1016/S0735-1097(01)01161-5 The chemical structures of the 10 ACE inhibitors currently available in the U.S. The term “proven” refers to ACE inhibitors shown to improve survival or reduce morbidity. ACEI = angiotensin-converting enzyme inhibitor. Figure Legend:
  • 18. CAPTOPRIL (CAPOTEN) • Captopril was the first inhibitor for clinical trial. • Reported to have a more favorable effect on QOL (Testa et al, 1993) • According to the mechanism proposed by Ondetti and colleagues, captopril interacts with the enzyme through several bonds, i.e. electrostatic, hydrogenic and lipophilic connections. • Among these, a co-ordinance bond formed between the free thiol group of captopril and zinc ion in the active site of ACE. 18
  • 19. Captopril contd • INTERRACTION OF CAPTOPRIL WITH ACE BINDING SITES(Vane, 1999 ) 19
  • 20. Captopril contd • Captopril, the first ACE inhibitor to be marketed, is a potent ACE inhibitor. • It is the only ACE inhibitor approved for use in the United States that contains a sulfhydryl moiety. • Given orally, captopril is absorbed rapidly and has a bioavailability of about 75%. • Peak concentrations in plasma occur within an hour, and the drug is cleared rapidly with a half-life of approximately 2 hours 20
  • 21. Captopril contd • Most of the drug is eliminated in urine, 40% to 50% as captopril and the rest as captopril disulfide dimers and captopril-cysteine disulfide. • The oral dose of captopril ranges from 6.25 to 150 mg two to three times daily, with 6.25 mg three times daily or 25 mg twice daily being appropriate for the initiation of therapy. • Most patients should not receive daily doses in excess of 150 mg. Since food reduces the oral bioavailability of captopril by 25% to 30%, the drug should be given 1 hour before meals 21
  • 22. Lisinopril (PRINIVIL, ZESTRIL). • Lisinopril, the third ACE inhibitor approved for use in the United States, is the lysine analogue of enalaprilat; unlike enalapril, lisinopril itself is active (Goodman ad Gilman, 2004). • In vitro, lisinopril is a slightly more potent ACE inhibitor than is enalaprilat. Lisinopril is absorbed slowly, variably, and incompletely (about 30%) after oral administration (not reduced by food); peak concentrations in plasma are achieved in about 7 hours. • It is cleared as the intact compound by the kidney, and its half-life in plasma is about 12 hours.
  • 23. Lisinopril contd • Lisinopril does not accumulate in tissues. • The oral dosage of lisinopril ranges from 5 to 40 mg daily (single or divided dosage), with 5 and 10 mg daily being appropriate for the initiation of therapy. • A daily dose of 2.5 mg is recommended for patients with heart failure who are hyponatremic or have renal impairment 23
  • 26. Counselling points for ACEIs • Might feel dizzy when you start taking this medicine. Get up gradually from sitting or lying position to minimize this effect. Sit or lie down if patient becomes light headed or dizzy. • Do not take potassium supplements or consume too much banana while taking this medication unless your doctor instructs otherwise. • When starting ACEIs, stop potassium-sparing diuretics, for 24 hours. • Always start with low doses. • Check renal function and electrolytes before starting ACEIs and review after 1-2 weeks. • Report promptly when untoward effects occur. 26
  • 27. Common side effects of ACEIs • Angioedema • Fetotoxicity • Skin rashes (esp. Captopril due to sulfhydryl group) • Acute renal failure • Dry cough • Headache • Nausea • Dizziness • Fatigue 27
  • 28. DISCUSSION • ACEIs increase survival when administered early after an acute myocardial infarction (MI) (Khalil et al). • The early benefit of ACE inhibitor therapy suggests that starting ACE inhibitors within 24 h has an effect on the infarcted myocardium either by limiting infarct size or by reducing infarct expansion (GISSI Trial, 1994) 28
  • 29. Effect of ACE-inhibitor therapy on cumulative mortality during days 0 to 30 in all trials combined. ACE Inhibitor Myocardial Infarction Collaborative Group Circulation. 1998;97:2202-2212 Copyright © American Heart Association, Inc. All rights reserved.
  • 30. DISCUSSION contd • Since activation of the renin-angiotensin system has been shown to be an independent predictor of ischemic event (Alderman et al, 1991), ACEIs help prevent MI. • Additionally, ACE inhibition has been shown to counteract several atherosclerotic processes including thrombosis, lowdensity lipoprotein oxidation, proliferation of vascular smooth muscle cells and local accumulation of neutrophils contributing to MI (Mancini, 1996). • Preliminary data have shown that ACE inhibition improves endogenous fibrinolytic function (Moriyama et al 1997). 30
  • 31. CONCLUSION • ACEIs have proven to be aces in the hole for virtually all cardiac patients as the RAAS appears to be a constant meddler in majority of cardiovascular events, which contribute a high percentage to morbidity and mortality worlwide. • They have a proven efficacy in the management of MI especially when started early in the post-infarction period. • A meta-analysis of all published, major trials investigating the use of an ACEI after an MI conclusively supports a role for ACEI therapy in the early phase and ongoing management of MI (Latini et al, 1995). 31
  • 32. REFERENCES • FitzGerald RJ, Murray BA, Walsh DJ; Murray, BA; Walsh, DJ (2004). "Hypotensive peptides from milk proteins". The Journal of nutrition 134 (4): 980S–8S. PMID 15051858 • Goodman & Gilman's The Pharmacological Basis Of Therapeutics - 11th Ed. (2006) • Bell, L., and Madri, J.A. Influence of the angiotensin system on endothelial and smooth muscle cell migration. Am. J. Pathol., 1990, 137:7-12. PUBMED • Daemen, M.J.M.P., Lombardi, D.M., Bosman, F.T., and Schwartz, S.M. Angiotensin II induces smooth muscle cell proliferation in the normal and injured rat arterial wall. Circ. Res., 1991, 68:450-456. PUBMED • 32
  • 33. REFERENCES • Villarreal, F.J., Kim, N.N., Ungab, G.D., Printz, M.P., and Dillmann, W.H. Identification of functional angiotensin II receptors on rat cardiac fibroblasts. Circulation, 1993, 88:2849-286l. PUBMED • Crawford, D.C., Chobanian, A.V., and Brecher, P. Angiotensin II induces fibronectin expression associated with cardiac fibrosis in the rat. Circ. Res., 1994, 74:727-739. PUBMED • Ostrom, R.S., Naugle, J.E., Hase, M., et al. Angiotensin II enhances adenylyl cyclase signaling via Ca++/calmodulin: Gq-Gs cross-talk regulates collagen production in cardiac fibroblasts. J. Biol. Chem., 2003, 278:24461-24468. PUBMED • Testa, M.A., Anderson, R.B., Nackley, J.F., Hollenberg, N.K., and the Quality-of-Life Hypertension Study Group. Quality of life and antihypertensive therapy in men: A comparison of captopril with enalapril. New Engl. J. Med., 1993, 328:907-913. PUBMED 33
  • 34. REFERENCES • Itoh, H., Mukoyama, M., Pratt, R.E., Gibbons, G.H., and Dzau, V.J. Multiple autocrine growth factors modulate vascular smooth muscle cell growth response to angiotensin II. J. Clin. Invest., 1993, 91:2268-2274. PUBMED • Scott-Burden, T., Hahn, A.W.A., Resink, T.J., and Buhler, F.R. Modulation of extracellular matrix by angiotensin II: Stimulated glycoconjugate synthesis and growth in vascular smooth muscle cells. J. Cardiovasc. Pharmacol., 1990, 16(suppl. 4):S36-S41 • Rajeev Kumar, Ramji Sharma, Khamji Barwa, Ram kumar Roy, Aran Kumar, Atul Baruwa. Moder developmet in ACE Ihibitors. Der Pharmacia Lettre, 2010; 2(3):388-419 • Mohammed E. Khalil, Abul W. Basher, Edward J. Brown, JR, Imad A. Alhaddad. A Remarkable Medical Story: Benefits of Angiotensin-Converting Enzyme Inhibitors in Cardiac Patients. Journal of the American College of Cardiology. 2001. 37(7): 34
  • 35. REFERENCES • Gruppo Italiano per lo Studio della Sopravvivenza nell’Infarto Miocardico. GISSI-3: effects of lisinopril and transdermal glyceryl trinitrate singly and together on six-week mortality and ventricular function after acute MI. Lancet 1994;343:1115–22 • Ng, K.K.F. & Vane, J.R. Conversion of angiotensin I to angiotensin II. Nature 216, 762–766 (1967) 35
  • 36. CREDITS: • Pharm. Khadijat S Adejumo • Pharm. Nicholas A • Pharm. Ibrahim James Oyibo • Mr Isa Buba and Mr Nasiru THANK YOU ALL FOR LISTENING. QUESTIONS? 36

Notas do Editor

  1. Effect of ACE-inhibitor therapy on cumulative mortality during days 0 to 30 in all trials combined.